FDA approves Stiolto Respimat (tiotropium bromide and olodaterol) for COPD- Boehringer

Boehringer Ingelheim announced that the FDA approved once-daily Stiolto Respimat (tiotropium bromide and olodaterol) Inhalation Spray as a long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Stiolto Respimat is not indicated to treat asthma or acute deterioration of COPD.

Comment; Stiolto Respimat is the fourth Respimat inhaled drug that the FDA has approved for market for chronic obstructive pulmonary disease. Stiolto Respimat is a once a day treatment that improves lung function in just five minutes and reduces patients� dependence on rescue inhalers. In clinical trials of more than 5,000 patients with differing severities of COPD, Stiolto Respimat was able to provide greater improvements in lung function than Spiriva Respimat (tiotropium bromide) or Striverdi Respimat (olodaterol) alone. Spiriva Respimat was launched in the U.S. market in January 2015, following FDA approval in September. Striverdi Respimat was approved a month earlier, while the older Combivent Respimat (ipratropium bromide & albuterol) gained approval in 2011.